1. Swiss Chinese
Life Sciences Forum 2021
June 30, 2021, 9:30 am – 12:00 pm
Slide 1

2. Hengrui Europe Therapeutics in Switzerland –
gateway to Europe
Dr. Michael van der Laan, MD
Head of Clinical Development Europe
Swiss Chinese Life Sciences Forum, June 30th 2021

3. Overview of Hengrui Pharmaceuticals
2
Note: [1] Market capitalization data cutoff date: 21st, May, 2021
~70[1] billion USD in market capitalization
>28,000 employees worldwide
220+ clinical trials ongoing worldwide

4. 3
A clinical team of 2000+ professionals running 220+ trials
Hengrui Pharma conducts most of its clinical trials using in-house capabilities that cover medical, trial
operations, data management, statistics, and regulatory. This allows us to better control speed and quality.
220+
clinical trials ongoing

5. 4
Ten Manufacturing Facilities
We fully own and control the manufacturing process and are typically able to produce
products at a competitive cost level. Majority of the facilities maintain USP and EUP.
Chengdu
Lianyungang
Shanghai
Xiamen
Suzhou
Wuhan
Guangzhou
Jinan
Tianjin
Beijing

6. 5
Fifteen R&D Centers Around the Globe
We have 15 R&D centers where over 4,700 research staff work on hundreds of therapeutic candidates, many
of which may become first-in-class or best-in-class products.
New Jersey
Nanjing
Lianyungang
Shanghai
R&D
Japan
Shanghai
Medical
Jinan
Boston
Xiamen
Basel
Suzhou
R&D
Guangzhou
Wuhan
Beijing Tianjin

7. 1,4 2,0 2,4 3,0 3,7
4,6
5,4
6,2
7,5
9,3
11,1
13,8
17,4
23,3
27,7
6,9
0,2 0,4 0,4 0,7 0,7 0,9 1,1 1,2 1,5 2,2 2,6 3,2
4,1
5,3
6,3
1,5
0,0
5,0
10,0
15,0
20,0
25,0
30,0
Revenue Net Profit
Annual Revenue and Net Profit Since 2006
6
Growth in Corporate Income
Our revenue in 2020 exceeded 4.26 billion USD (27.7 billion RMB).
(Billion RMB)
2020 vs. 2019
↑ 19.1%
YoY
↑ 25.4%

8. 7
Commitment to Innovation
120 160 200 255 300 400 535 563 650
892
1 184
1 759
2 670
3 896
4 989
1 316
0
1000
2000
3000
4000
5000
6000
Annual R&D Spending Since 2006
We spent 768 million USD (4.99 billion RMB) in R&D in 2020, which is nearly 18% of the 2020 revenue.
(Million RMB)
2020 vs. 2019
↑ 28.0%
YoY
↑ 62.3%

9. Other
Pain
Autoimmune
Cardiovascular
& Metabolics
Oncology
Broad Pipeline Focusing on Unmet Medical Needs (China)
8
SHR6390
CDK4/6
Breast Cancer
Camrelizumab ★
PD-1
cHL/HCC/EC/NSCLC/NPC
Mecapegfilgrastim ★
PEG-G-CSF
Neutropenia
SHR2554
EZH2
Lymphoma
SHR-1501 ★
IL-15
Solid Tumors
SHR1459
BTK
Lymphoma
SHR-1702 ★
TIM-3
Solid/Hematological Tumors
Fuzuloparib
PARP
BRCAm OC
SHR-1316 ★
PD-L1
SCLC/NSCLC
SHR3680
AR
Prostate Cancer
Famitinib
VEGFR2/c-Kit/PDGFR
GIST
Apatinib
VEGFR2
Gastric Cancer/HCC
Pyrotinib
EGFR/HER2/HER4
HER2+ Breast Cancer
SHR0532
ROMK
Hypertension
SHR-1209 ★
PCSK9
Hypercholesterolemia
INS068 ★
Basal Insulin
Diabetes
SHR20004 ★
GLP-1 (SC)
Metabolic Diseases
Retagliptin
DPP-4
Type II Diabetes
Henagliflozin
SGLT2
Type II Diabetes
SHR0410
KOR
Analgesia
SHR8554
MOR
Analgesia
Imrecoxib
COX-2
Osteoarthritis
SHR4640
URAT1
Gout/Hyperuricemia
Hetrombopag
TPOR
ITP/Aplastic Anemia
SHR8028
Calcineurin
DED
SHR8058
Lipid Regulator
DED
SHR8008
CYP51
RVVC/VVC
Fuzuloparib
PARP
OC/BC/Pancreatic Cancer
SHR7280
GnRH
Endometriosis
SHR2285
FXI
Anticoagulation
DDO-3055
HIF-PH
Renal Anemia
SHR0302
JAK1
RA/AS
Pyrotinib
EGFR/HER2/HER4
HER2m NSCLC
Phase I
NDA
Launched
Phase II
Phase III
Large Molecule
SHR-A1811★
HER2 ADC
Solid Tumors
SHR-1802★
LAG-3
Solid Tumors
SHR-1703 ★
IL-5
Asthma
Anti-Infection
Fuzuloparib
PARP
Recurrent OC Maintenance
SHR0302
JAK1
AD/UC/CD/AA
SHR-1701 ★
PD-L1/TGF-β
Pancreatic Cancer/NSCLC
Pyrotinib
EGFR/HER2/HER4
HER2m BTC
SHR-1314 ★
IL-17
AS/PsO
Remimazolam
GABAα
Gastroscopy Sedation/
Colonoscopy Sedation
Remimazolam
GABAα
General Anaesthesia
Remimazolam
GABAα
Fibrobronchoscope Sedation
HRS9950
TLR8
HBV
HRS5091
Core Protein
HBV
SHR-1916 ★
PEG-IL-2
Advanced Tumors
SHR-1707 ★
Aβ
Alzheimer’s Disease
SHR-1222 ★
SOST
Osteoporosis

10. 謝謝
Swiss Chinese Life Sciences Forum, June 30, 2021

11. Chinese Investment in
Swiss Biotech Startups
The Case of Viva BioInnovator

12. 2
Why do Chinese Investors look at Switzerland?
Many early-
stage
investors to
form
syndicates
Robust
ecosystems
with biotech
clusters
Established
pool of
pharma
leaders
Competitive
Valuations
Cutting edge
university
innovation

13. 3
3
Investment Criteria
Valuable
Innovation
The “idea” needs to be
differentiated and
address true unmet
medical need.
Switzerland has 12
highly ranked
universities.
Strong Team
The management team should
have strong integrity, a track
record of company building,
and experience in drug R&D.
Multiple local Swiss pharma
companies leading to many
experienced advisors and
founders.
Commercial
Viability
There must be
significant market
potential 5-10 years
in the future.
Many Swiss
companies are
focusing on more
novel drugs.
Strategic Fit
What interests us from early-stage companies?
Focus on early-stage
therapeutics and in-
kind investment (EFS)
opportunities.
Swiss ecosystem
supports many early-
stage companies.

14. 4
VBI Project Sourcing Network
35Universities & Research
Institutes
29Accelerators &
Incubators
47Investment Institutions Funds &
Networks
Viva BioInnovator sources projects globally and reviews over 1000 projects annually, but Europe and Switzerland in particular is
a key area of growth interest for VBI.

15. 5
VBI Summary of Portfolio Statistics
Growing Portfolio of Cutting-Edge Biotech Start-ups
Indication
Metabolic & CVD
Oncology/Cancer
CNS
Infection/immune
others
Modality
Small molecule
Macromolecule
Genes & cell therapy
Others
Location
US
China
Canada
Switzerland
Germany
As of June 2021, We have a approximately 65portfolio companies, with 3 Swiss investments made recently.

16. 6
Portfolio Companies
Our Portfolio Covers a Wide Spectrum of Therapeutic Areas
CNS Infectious
Immunology
Oncology
Proviva
Clues
Metabolic
Regenerative
Analgesic
Dermatology &
Ophthalmology
Cardiovascular

17. 7
Investor
What do Swiss start-ups gain from having a Chinese Investor?
Virtual Incubator Focused on Pre-Clinical and Novel Therapeutics
We work with some of the world's
brightest minds to help discover
novel and life-changing
therapeutics.
We specialize in the development
of biotech startups that turn
brilliant ideas into clinical products.
Virtual Incubator
• Realize the "0 to 1"
Transformation
• Established Support Ecosystem
Partner
• Help Ensure Your Success
• Minority Shareholder
• Catalyze Innovation and Growth
• ~60 portfolio companies (2020)
Viva BioInnovator is committed to being a
Collaborative Platform for Innovative Biotech Companies
from around the world.

18. 8
8
Post Investment Support
Optimized Virtual Incubation Platform
Capital Industry
Networks Operations
• Lab and office locations in Shanghai, Jiaxing,
Chengdu, and Hangzhou.
• “Back-office” support (HR, Accounting, BD, etc. )
• Assistance in procuring internal or external resources
• Will alert founders to changes in market dynamics
• Trusted CRO referrals
• Introduction to Chinese investors for later-stage
funding and financial advice.
• China market introductions for out-licensing,
development of China rights, and more.
• Our leading CRO platforms are
productive and efficient
CRO
Service
An Innovative Idea and Entrepreneurship is all you need for this more hands-on post-investment support.
• Evergreen investment focused
on Seed and Series A
Each company will have an
option to receive a:
• Venture Partner for
management support
• Venture Advisor for
scientific consultation
Expert
Support

19. 9
Our Partnership Platforms
200+ Investors at Each Demo Day
Regular opportunities for a small number of
portfolio companies to connect with top-tier
investors and pharma companies.
VBI Demo Days
2nd
Annual Partnership Summit
300+ Attendees from around the world
Featured Viva’s portfolio companies with
1-on-1 meetings, expert panels, roadshow
presentations, and more.

20. 10
Concept Discovery PCC CMC/IND Phase I A
Phase I B
and Beyond
We Provide the First Thrust to Biotech Startups
• Seed round to A-round, with an average investment amount between $0.5 million- $5 million.
• Can invest larger amounts for a limited selection of projects.
• VBI can lead, co-lead, syndicate, or be a follow-on investor.
• Investments can be cash only, EFS (Equity for Service) only, or a combination of both.
• We will only consider therapeutics.
VBI Provides the First Thrust to Therapeutic Startups
Our Preferred Investment Range

21. 11
11
Your Partner for Innovation and Growth
VIVA BioInnovator——Ecosystem
MNC
Pharma
Biotech
Startups
Research
Institutes
Investors
VC/PE
Incubators
Top
Scientists
Our next location…

22. www.vivabioinnovator.com
www.vivabiotech.com.cn
Viva BioInnovator
Contact Us
chloe.kamps@vivabiotech.com
Disclaimer
This document is prepared by Viva Biotech/VIVA BioInnovator. This document has been prepared for the recipient’s information purpose
only. The recipient shall conduct its own investment review, evaluation and assessment.
This document is not and shall not to be construed as an offer to sell or a solicitation of an offer to buy any security in any jurisdiction. Viva
Biotech/VIVA BioInnovator does not provide any representations, warranties or any other assurances with respect to the contents of this
document. Viva Biotech/VIVA BioInnovator does not act for the recipients of this document. Distribution of this document in or from certain
jurisdictions may be restricted or prohibited by law or regulations. Recipients are required to comply with all restrictions or prohibitions in
such jurisdictions.
Viva Biotech/VIVA BioInnovator disclaims any liability over the use, misuse, reliance, distribution or possession of this document which shall
be at the recipient’s own risk. Neither this document nor any of its contents may be disclosed or used for any other purpose without the
prior written consent of Viva Biotech/VIVA BioInnovator. If the recipient has any question, the recipient shall seek its own independent
advice.

23. China’s new Dual Circulation Strategy – how are
life science companies affected•
June 30, 2021
Swiss-Chinese Life Science Forum
Lukas Zuest, Swiss Attorney-at-Law, Head China Desk, VISCHER AG

24. China's "Dual Circulation" strategy 2
Content
• China’s dual circulation strategy
• Life Science industries in the 14th 5-year plan for 2021-2025
• Opportunities and challenges for Swiss and Chinese life science
companies
China’s new “Dual Circulation” strategy – How are life
science companies affected•

25. A strategy to reorient China’s economy by prioritizing
domestic consumption ("internal circulation") while
remaining open to international trade and investment
("external circulation")
China’s “Dual Circulation” Strategy•
China's "Dual Circulation" strategy 3

26. • First articulated in May 2020; further specified by President Xi
Jinping during 2020
• Set to determine legislative, diplomatic and economic
developments in China for the coming decade
China’s “Dual Circulation” Strategy•
China's "Dual Circulation" strategy 4

27. Main objectives:
• Eliminating its dependence on foreign technology in strategic sectors
(technical self-sufficiency)
• Facilitating the domestic dominance of local companies in key sectors
• Boosting private consumption in China: 39% of GDP; compared to an
average of 55% of other major economies
• Leveraging the domestic dominance into global competitiveness
 Continuation of a process that started already in 2005
China’s “Dual Circulation” Strategy•
China's "Dual Circulation" strategy 5

28. China's "Dual Circulation" strategy 6
• Improving domestic economic conditions
• Boosting technological innovation
• Key industries identified, amongst them:
 Neuroscience and brain-inspired research
 Genetic research
 Biotechnology
 Clinical medicine and health
Life science industry in the 14th 5-years plan 2021-
2025•

29. China's "Dual Circulation" strategy 7
Innovation
• Massive increase of R&D spending
• Growth of more than 7% per annum
• Starting from 2.3% share of GDP (2020) to 2.7% (2025)
• To facilitate: tax rebates on R&D spending will be introduced
• Comparison:
 EU: 2.2% (2017)
 USA: 2.8% (2018)
 Switzerland: 3% (2017)
Life science industry in the 14th 5-years plan 2021-
2025•

30. China's "Dual Circulation" strategy 8
Local policies (for example Biomedical industry policy of Shanghai)
• Aim to establish policies to support the entire value chain (from
R&D to application)
• Supporting fields: antibody drugs, new vaccines, gene therapy,
cell therapy, high-end medical devices, advanced equipment
• Subsidies for overseas market development: <30% of the R&D
investments, and <RMB 10 million one-off payment.
Life science industry in the 14th 5-years plan 2021-
2025•

31. China's "Dual Circulation" strategy 9
Opportunities
• Life science as a key industry attracts high attention
• Policy driven support
• Governmental subsidies and preferential (tax) treatment
• Chinese venture capital for Swiss life science startups
Opportunities and challenges for Swiss and Chinese life
science companies•

32. China's "Dual Circulation" strategy 10
Challenges
• Life science is a key industry: Chinese industry policy will be
decisive in the mid to long-term
 Have a clear long-term strategy
• Multinational: R&D and manufacturing in China – competition
from indigenous firms will increase
• Swiss startups: Granting commercialisation rights for China to
Chinese investor/partner as an option
Opportunities and challenges for Swiss and Chinese life
science companies•

33. China's "Dual Circulation" strategy 11
Key takeaways:
• Dual circulation strategy logical continuation of China’s economic
policy initiated in 2005
• Life science will be a key industry in China in this decade
Takeaways•

34. 12
Lukas Zuest
Counsel
Head China Desk
Swiss Attorney at Law, LL.M.
lzuest@vischer.com
+41 58 211 34 35
Your contacts at VISCHER•
China's "Dual Circulation" strategy
YAO Qinqin, LL.M.
Legal Expert, China Desk
qyao@vischer.com
+41 58 211 36 56